

InnoCan Pharma

08:30 04 May 2020

InnoCan Pharma appoints Professor Daniel Offen as scientific advisor following Tel Aviv University deal

InnoCan Pharma Corporation (CSE:INNO) has announced that cell and gene therapy specialist Professor Daniel Offen had been appointed to its scientific advisory committee following the firm's tie-up with Tel Aviv University company, Ramot.

Professor Offen works at the Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Sagol School of Neuroscience at Tel Aviv University.

READ: InnoCan Pharma Corp announces tie-up with Tel Aviv University for new treatment for coronavirus pandemic

"We, InnoCan Pharma and the University of Tel Aviv are joining the forces now to develop, what we expect to be, a revolutionary approach to fight multiple diseases," Professor Offen said in a statement.

"Based on my personal experience, I feel that our approach treating (coronavirus) COVID-19 disease with a combination of exosomes and CBD molecules hold a great potential."

He also noted that Exosomes research was a relatively new field in the stem cell sector. Exosomes are small particles created when stem cells are multiplied. They can act as "homing missiles", targeting specific damaged organs and have an important role in cell-to-cell communication.

Last month, Innocan revealed that CBD-loaded Exosomes hold the potential to provide anti-inflammatory properties and help infected lung cells to recover.

Professor Offen studied molecular biology at the Weizmann Institute of Science, Israel and went on to the Albert Einstein College of Medicine in New York as a post-doctoral fellow. He has published over 200 articles, review papers and book chapters and had file over 30 granted patents.

Contact the author at giles@proactiveinvestors.com

Price: 0.215

Market Cap: \$30.93 m

1 Year Share Price Graph



Share Information

Code: INNO

Listing: CSE

52 week High Low
0.4 0.05

Sector: Cannabis

Website: innocanpharma.com

Company Synopsis:

Innocan Pharma™ combines pharmaceutical experience with technological innovation to deliver the new generation of CBD integrated pharma and cosmetics products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).